A heterogeneous pharmaco-transcriptomic landscape induced by targeting a single oncogenic kinase

Area of Science:

• Oncology
• Molecular Biology
• Genomics

Background:

• Over-activation of the epidermal growth factor receptor (EGFR) is a key characteristic of glioblastoma, a deadly brain cancer.
• Despite this, EGFR-targeted therapies have yielded minimal clinical benefits, partly due to challenges in drug delivery to the brain and a poor understanding of drug-specific efficacy factors.

Purpose of the Study:

• To investigate the molecular responses of glioblastoma to epidermal growth factor receptor inhibitors (EGFRis) using advanced chemical genomics.
• To identify drug-specific features that influence the efficacy of EGFRis beyond brain penetration.

Main Methods:

• Utilized highly multiplex single-cell chemical genomics to analyze glioblastoma's response to various EGFRis.
• Employed a deep generative framework to decipher shared and drug-specific transcriptional programs induced by EGFRis.

Main Results:

• EGFRis were classified into distinct molecular groups based on their unique and shared transcriptional programs.
• Identified chemical property-dependent programs, including adaptive transcription and modulation of immunogenic gene expression.
• Demonstrated that certain tyrphostin family EGFRis induce pro-immunogenic changes, enhancing T-cell-mediated targeting of glioblastoma cells.

Conclusions:

• The study reveals distinct molecular classes of EGFRis based on their transcriptional effects in glioblastoma.
• Chemical properties of EGFRis significantly influence adaptive and immunogenic responses.
• Specific EGFRis can enhance glioblastoma's immunogenicity, offering a potential strategy to improve immunotherapy outcomes.